The company's financial health has deteriorated rapidly, with total assets falling from $91.9 million in 2023Q4 to $59.9 million by 2025Q4, while retained earnings have plummeted to a $73.1 million deficit.
| Metric | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Total Current Assets | 3.15M | 30.64M | 47.59M | 60.83M | 61.32M | 15.89M | 9.95M | 18.24M | 28.92M | 9.63M | 11.88M | 13.46M | 11.28M | 10.72M | 13.2M | 15.76M | 17.23M | 20.67M | 28.84M | 29.79M | 30.25M | 24.96M | 23.74M | 22.48M | 22.18M | 23.47M | 30.7M | 47M | 49.2M | 1M |
| Cash & Short-Term Investments | 90K | 678K | 4.74M | 17.44M | 17.51M | 8.46M | 1.36M | 8.24M | 21.94M | 441K | 1.66M | 2.93M | 1.64M | 572K | 5.54M | 8.23M | 12.8M | 11.96M | 16.09M | 17.76M | 16.89M | 14.37M | 11.39M | 12.9M | 9.74M | 11.37M | 14M | 28.3M | 25.5M | 400K |
| Cash Only | 90K | 678K | 1.61M | 9.11M | 8.66M | 6.82M | 434K | 1.55M | 3.17M | 441K | 1.66M | 2.93M | 1.64M | 0 | 5.54M | 8.23M | 12.8M | 11.96M | 16.09M | 17.76M | 16.89M | 14.37M | 11.39M | 12.9M | 9.74M | 11.37M | 14M | 28.3M | 25.5M | 400K |
| Short-Term Investments | 0 | 0 | 3.13M | 8.33M | 8.86M | 1.64M | 926K | 6.69M | 18.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.54M | 20.06M | 35.81M | 37.05M | 37.71M | 3.15M | 6.82M | 7.8M | 1.95M | 5.77M | 4M | 5.84M | 5.32M | 5.41M | 3.22M | 4.82M | 2.09M | 4.52M | 6.67M | 6.56M | 7.88M | 6.38M | 7.86M | 4.19M | 4.18M | 4.06M | 6.6M | 7.6M | 10.9M | 600K |
| Days Sales Outstanding | 129.03 | 1.08K | 294.52 | 110.27 | 174.13 | 79.34 | 252.13 | 216.84 | 71.95 | 100.22 | 70.86 | 96.52 | 77.56 | 88.11 | 67.32 | 121.34 | 38.42 | 80.51 | 61.7 | 56.82 | 53.6 | 52.95 | 69.15 | 51.96 | 61.78 | 76.58 | 97.14 | 76.21 | 56.67 | 273.75 |
| Inventory | 70K | 1.14M | 2.29M | 3.98M | 4.6M | 3.04M | 1.46M | 1.9M | 1.53M | 2.74M | 4.33M | 3.29M | 2.52M | 2.05M | 2.69M | 1.68M | 1.41M | 3M | 4.81M | 4.26M | 3.9M | 3.45M | 3.75M | 4.53M | 6.51M | 6.92M | 6.2M | 6.5M | 7.7M | 100K |
| Days Inventory Outstanding | 8.63 | 60.29 | 29.71 | 27.91 | 36.32 | 111.95 | 73.34 | 83.23 | 70.57 | 91.22 | 187.61 | 152.27 | 110.05 | 91.81 | 158.99 | 108.24 | 62.18 | 120.45 | 104.37 | 80.83 | 55.12 | 53.49 | 63.75 | 96.01 | 247.04 | 429.09 | 293.9 | 221.73 | 131.95 | - |
| Other Current Assets | 1.45M | 8.76M | 4.74M | 2.37M | 1.5M | 1.24M | 304K | 296K | 2.86M | 417K | 1.88M | 519K | 501K | 2.69M | 1.75M | 138K | 138K | 1.19M | 1.27M | 1.22M | 1.58M | 764.36K | 0 | 374.01K | 782.26K | 1.12M | 3.9M | 4.6M | 5.1M | -100K |
| Total Non-Current Assets | 56.72M | 32.56M | 44.34M | 26.81M | 27.98M | 15.52M | 2.33M | 2.5M | 5.24M | 3.17M | 2.95M | 2.6M | 6.14M | 5.94M | 5.88M | 5.94M | 2.58M | 3.7M | 4.48M | 5.05M | 5.73M | 6.57M | 2.53M | 2.46M | 2.57M | 2.59M | 2.6M | 1.6M | 600K | 400K |
| Property, Plant & Equipment | 2.03M | 11.62M | 14.9M | 11.35M | 10.35M | 8.31M | 2.33M | 2.5M | 2.74M | 3.17M | 2.95M | 2.6M | 2.56M | 2.37M | 2.31M | 2.36M | 2.57M | 3.67M | 4.36M | 4.84M | 5.59M | 6.47M | 2.42M | 2.34M | 2.2M | 2.14M | 1.9M | 1M | 200K | 100K |
| Fixed Asset Turnover | 2.14x | 0.58x | 2.98x | 10.81x | 7.64x | 1.75x | 4.24x | 5.25x | 3.60x | 6.62x | 6.98x | 8.49x | 9.76x | 9.47x | 7.57x | 6.14x | 7.70x | 5.59x | 9.06x | 8.71x | 9.61x | 6.79x | 17.16x | 12.59x | 11.21x | 9.05x | 13.05x | 36.40x | 351.00x | 8.00x |
| Goodwill | 3.97M | 5.23M | 5.23M | 5.71M | 5.71M | 901K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30.76K | 327.01K | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 7.17M | 9.75M | 12.33M | 8.47M | 10.85M | 1.23M | 0 | 0 | 0 | 0 | 0 | 0 | 3.58M | 3.58M | 3.58M | 3.58M | 0 | 0 | 0 | 0 | 30.76K | 30.76K | 30.76K | 0 | 21.94K | 438.87K | 200K | 300K | 400K | 200K |
| Long-Term Investments | 43.49M | 0 | 0 | 0 | 0 | 2.75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.45K | 26.45K | 26.45K | 0 | 26.45K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 63K | 5.97M | 4.56M | 1.28M | 1.07M | 2.32M | 0 | 0 | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12K | 9K | 96.76K | 187.2K | 110.86K | 37.39K | 80.36K | 91.37K | 24.19K | 7.3K | 500K | 300K | 0 | 100K |
| Total Assets | 59.87M | 63.2M | 91.93M | 87.65M | 89.3M | 31.41M | 12.27M | 20.74M | 34.16M | 12.8M | 14.83M | 16.06M | 17.42M | 16.66M | 19.08M | 21.7M | 19.82M | 24.37M | 33.31M | 34.85M | 35.98M | 31.53M | 26.27M | 24.93M | 24.76M | 26.06M | 33.3M | 48.6M | 49.8M | 1.4M |
| Asset Turnover | 0.07x | 0.11x | 0.48x | 1.40x | 0.89x | 0.46x | 0.80x | 0.63x | 0.29x | 1.64x | 1.39x | 1.37x | 1.44x | 1.34x | 0.91x | 0.67x | 1.00x | 0.84x | 1.18x | 1.21x | 1.49x | 1.39x | 1.58x | 1.18x | 1.00x | 0.74x | 0.74x | 0.75x | 1.41x | 0.57x |
| Asset Growth % | -5.27% | -31.25% | 4.88% | -1.84% | 184.33% | 155.87% | -40.81% | -39.3% | 166.84% | -13.67% | -7.65% | -7.82% | 4.56% | -12.67% | -12.06% | 9.48% | -18.68% | -26.85% | -4.39% | -3.14% | 14.1% | 20.02% | 5.35% | 0.72% | -4.99% | -21.75% | -31.48% | -2.41% | 3457.14% | - |
| Total Current Liabilities | 53.08M | 32.13M | 20.86M | 16.07M | 15.52M | 6.29M | 933K | 4.23M | 1.81M | 6.84M | 4.53M | 5.24M | 4.62M | 4.91M | 7.85M | 8.23M | 5.76M | 6.59M | 10.02M | 9.25M | 9.57M | 7.11M | 5.48M | 6.51M | 3.56M | 4.85M | 7.1M | 4M | 8.1M | 100K |
| Accounts Payable | 12.96M | 13.72M | 8.64M | 5.91M | 7.03M | 3.77M | 432K | 437K | 562K | 2.16M | 990K | 667K | 1.01M | 1.3M | 885K | 489K | 482K | 693.84K | 537.86K | 885.65K | 771.82K | 978.4K | 524.14K | 394.68K | 818.8K | 763.53K | 400K | 800K | 1.1M | 100K |
| Days Payables Outstanding | 1.6K | 723.51 | 112.1 | 41.45 | 55.47 | 138.92 | 21.72 | 19.11 | 25.9 | 71.88 | 42.89 | 30.85 | 44.14 | 58.01 | 52.35 | 31.47 | 21.33 | 27.85 | 11.67 | 16.8 | 10.91 | 15.15 | 8.9 | 8.37 | 31.08 | 47.36 | 18.96 | 27.29 | 18.85 | - |
| Short-Term Debt | 5.16M | 6.57M | 2.79M | 301K | 663K | 329K | 0 | 0 | 0 | 1.49M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 428.57K | 428.57K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1.5M | 1.7M | 2.38M | 2.5M | 2.03M | 169K | 104K | 206K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 50K | 8.03M | 2.6M | 2.93M | 3.92M | 1.52M | 310K | 3.2M | 1.25M | 3.02M | 3.06M | 4.2M | 3.26M | 3.61M | 6.73M | 7.26M | 4.89M | 5.69M | 9.48M | 8.13M | 7.44M | 4.98M | 2.01M | 1.74M | 1.2M | 4.08M | 6.7M | 3.2M | 7M | 0 |
| Current Ratio | 0.06x | 0.95x | 2.28x | 3.78x | 3.95x | 2.52x | 10.66x | 4.31x | 15.96x | 1.41x | 2.62x | 2.57x | 2.44x | 2.18x | 1.68x | 1.91x | 2.99x | 3.13x | 2.88x | 3.22x | 3.16x | 3.51x | 4.33x | 3.45x | 6.24x | 4.84x | 4.32x | 11.75x | 6.07x | 10.00x |
| Quick Ratio | 0.06x | 0.92x | 2.17x | 3.54x | 3.65x | 2.04x | 9.10x | 3.86x | 15.11x | 1.01x | 1.66x | 1.94x | 1.89x | 1.77x | 1.34x | 1.71x | 2.75x | 2.68x | 2.40x | 2.76x | 2.75x | 3.03x | 3.65x | 2.76x | 4.41x | 3.41x | 3.45x | 10.13x | 5.12x | 9.00x |
| Cash Conversion Cycle | -1.46K | 418.19 | 212.13 | 96.73 | 154.97 | 52.38 | 303.76 | 280.96 | 116.61 | 119.56 | 215.59 | 217.94 | 143.48 | 121.91 | 173.96 | 198.11 | 79.27 | 173.12 | 154.4 | 120.85 | 97.82 | 91.3 | 123.99 | 139.6 | 277.73 | 458.31 | 372.07 | 270.65 | 169.77 | - |
| Total Non-Current Liabilities | 3.28M | 23.71M | 21.69M | 7.94M | 15.14M | 14.55M | 110K | 0 | 0 | 0 | 1.47M | 100K | 200K | 300K | 0 | 0 | 0 | 0 | 0 | 0 | 1.04M | 2.46M | 524.14K | 394.68K | 911.81K | 763.53K | 400K | 800K | 1.1M | 100K |
| Long-Term Debt | 0 | 11.65M | 7.33M | 2.4M | 10.04M | 9.99M | 0 | 0 | 0 | 0 | 1.47M | 0 | 0 | 300K | 0 | 0 | 0 | 0 | 0 | 0 | 1.04M | 2.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 639K | 6.35M | 8.33M | 4.26M | 4.2M | 4.4M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 224K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2M | 4.92M | 4.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100K | 200K | 300K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 400K | 0 | 0 | 100K |
| Total Liabilities | 56.36M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M | 1.04M | 4.23M | 1.07M | 6.84M | 6M | 5.34M | 4.82M | 5.21M | 7.85M | 8.23M | 5.76M | 6.59M | 10.02M | 9.25M | 10.6M | 9.57M | 5.48M | 6.51M | 3.56M | 4.85M | 7.1M | 4M | 8.1M | 200K |
| Total Debt | 8.62M | 24.57M | 18.46M | 6.96M | 14.9M | 14.72M | 0 | 0 | 0 | 1.49M | 1.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.46M | 2.89M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Debt | 8.53M | 23.89M | 16.85M | -2.15M | 6.24M | 7.91M | -434K | -1.55M | -3.17M | 1.05M | -198K | -2.93M | -1.64M | 0 | -5.54M | -8.23M | -12.8M | -11.96M | -16.09M | -17.76M | -15.42M | -11.47M | -11.39M | -12.9M | -9.74M | -11.37M | -14M | -28.3M | -25.5M | -400K |
| Debt / Equity | 2.46x | 3.34x | 0.37x | 0.11x | 0.25x | 1.39x | - | - | - | 0.25x | 0.17x | - | - | - | - | - | - | - | - | - | 0.06x | 0.13x | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | 0.24x | 1.01x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.33x | 3.60x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | -0.07x | 0.42x | - | - | - | - | - | - | - | -2.49x | - | - | - | - | - | - | - | -3.52x | -14.26x | -10.27x | - | -151.62x | - | - | -2.86x | -0.72x | - |
| Interest Coverage | -2.37x | -11.64x | -16.88x | 30.98x | 5.62x | -6.84x | - | - | -73.89x | -17.81x | -115.33x | -782.40x | 32.15x | - | - | - | - | - | - | -53.78x | 29.70x | 5.70x | - | - | - | - | - | - | - | - |
| Total Equity | 3.51M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M | 11.23M | 16.5M | 31.85M | 5.96M | 8.83M | 10.72M | 12.6M | 11.45M | 11.23M | 13.46M | 14.06M | 17.77M | 23.3M | 25.59M | 25.37M | 21.96M | 20.79M | 18.42M | 21.2M | 21.21M | 26.2M | 44.6M | 41.7M | 1.2M |
| Equity Growth % | -52.29% | -85.11% | -22.39% | 8.53% | 455.4% | -6.01% | -31.95% | -48.18% | 434.17% | -32.47% | -17.61% | -14.93% | 10% | 2% | -16.6% | -4.26% | -20.9% | -23.71% | -8.97% | 0.86% | 15.56% | 5.63% | 12.83% | -13.1% | -0.04% | -19.05% | -41.26% | 6.95% | 3375% | - |
| Book Value per Share | 0.41 | 3.85 | 28.70 | 34.12 | 31.88 | 9.10 | 9.71 | 14.48 | 20.29 | 3.49 | 5.38 | 6.39 | 7.74 | 7.71 | 7.58 | 9.42 | 10.85 | 13.80 | 18.30 | 20.90 | 19.08 | 15.20 | 13.94 | 16.91 | 19.72 | 20.10 | 23.08 | 29.84 | 28.40 | 0.95 |
| Total Shareholders' Equity | 3.51M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M | 11.23M | 16.5M | 31.85M | 5.96M | 8.83M | 10.72M | 12.6M | 11.45M | 11.23M | 13.46M | 14.06M | 17.77M | 23.24M | 25.53M | 25.32M | 21.9M | 20.79M | 18.42M | 21.2M | 20.97M | 26.2M | 44.6M | 41.7M | 1.2M |
| Common Stock | 4K | 23K | 18K | 16K | 16K | 14K | 14K | 14K | 14K | 13K | 13K | 13K | 11K | 11K | 10K | 10K | 9K | 8.78K | 8.75K | 8.66K | 8.18K | 8.14K | 8.07K | 8.05K | 7.66K | 7.64K | 7.4M | 0 | 0 | 0 |
| Retained Earnings | -73.14M | -58.39M | -5.03M | 11.75M | 2.64M | -3.63M | -1.51M | 4.53M | 22.14M | -19.69M | -16.82M | -13.22M | -5.38M | -5.79M | -4.7M | -1.99M | 1.51M | 5.35M | 10.89M | 13.35M | 15.09M | 11.88M | 11.69M | 11.01M | 17.47M | 17.25M | 22.4M | 26.6M | 19.8M | -2.8M |
| Treasury Stock | -49.64M | -64M | -64M | -58.03M | -48.41M | -47.49M | -47.49M | -47.49M | -47.02M | -30.74M | -30.74M | -30.74M | -25.64M | -25.64M | -25.64M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.19M | -25.16M | -25M | -10.3M | 0 | 0 |
| Accumulated OCI | -198K | -198K | -300K | 757K | -175K | -11K | -2K | -24K | -78K | -5.13M | -4.71M | -4.34M | -4.06M | -3.86M | -3.61M | -3.39M | -3.15M | -4.87M | -4.95M | -4.03M | -3.17M | -1.82M | -1.45M | -1.02M | -812.39K | -520.33K | -300K | -200K | -100K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.09K | 63.56K | 54.31K | 54.98K | 0 | 0 | 0 | 237.33K | 0 | 0 | 0 | 0 |
Imminent liquidity and insolvency
As reported in recent financial filings, ProPhase Labs has seen its total assets decline from $91.9 million in 2023Q4 to $59.9 million by 2025Q4, signaling a rapid contraction in the company's resource base as it struggles to pivot away from its legacy diagnostic revenue streams.
The consistent decline in total assets alongside a ballooning deficit in retained earnings suggests that the company is consuming its capital base to fund ongoing operations. This trajectory indicates that the current business model is failing to generate the necessary scale to sustain its asset footprint.
Based on the most recent quarterly data, ProPhase Labs reports a cash balance of only $90,000, which, when paired with a current ratio of 0.06, indicates an extremely precarious liquidity position that leaves virtually no buffer against operational shocks or unexpected liabilities in the near term.
A current ratio of 0.06 is exceptionally low and suggests that current liabilities vastly outweigh the company's ability to meet them with liquid assets. Investors should monitor this closely, as the lack of cash reserves likely necessitates immediate and potentially dilutive external financing to maintain operations.
According to reported balance sheet figures, the company's debt-to-equity ratio has surged to 2.46 as of 2025Q4, reflecting a significant increase in leverage that appears driven by the necessity to fund operating losses rather than strategic growth initiatives or capital expansion projects.
The rising debt-to-equity ratio in the face of declining assets and negative retained earnings suggests that the company is increasingly reliant on debt to bridge its funding gap. This trend warrants investigation, as it increases the risk of insolvency if the company cannot secure additional capital.
As evidenced by the company's financial statements, retained earnings have plummeted to a deficit of $73.1 million by 2025Q4, indicating that years of operating losses have severely eroded the equity base and diminished the value attributable to common shareholders over the observed period.
The persistent decline in equity highlights the impact of sustained net losses on the company's balance sheet. This trend suggests that the firm's capital structure is becoming increasingly fragile, which may limit future financing options and increase the risk of significant shareholder dilution.
While the balance sheet carries $4.0 million in goodwill, the rapid decline in operational performance suggests that these intangible assets may be subject to future impairment charges, which would further weaken the company's already strained equity position and overall balance sheet health.
The presence of goodwill on the balance sheet during a period of significant revenue contraction and negative operating margins warrants further investigation. If the underlying business units fail to meet performance expectations, these assets may need to be written down, exacerbating the company's existing financial distress.
Quick answers to the most common questions about buying PRPH stock.
As of 2025, ProPhase Labs, Inc. (PRPH) had total assets of $59.9M including $3.1M in current assets.
ProPhase Labs, Inc. (PRPH) carries total debt of $8.6M, offset by $0.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ProPhase Labs, Inc. (PRPH) has total shareholders' equity (book value) of $3.5M ($0.41 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ProPhase Labs, Inc. (PRPH) reported a current ratio of 0.06x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.